Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,921 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Part 2 Clear all
Terminated Phase 3 Interventional Results available

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
View directory record Official record
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase-dependent Evaluation of Motor Cortex Excitability With TMS in Stroke

NCT04968743
View directory record Official record
Conditions
Stroke
Interventions
Transcranial magnetic stimulation (TMS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies

NCT05577182
View directory record Official record
Conditions
Advanced Malignancies
Interventions
INCA32459-101
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 2, 2026, 3:45 PM EDT
Active, not recruiting No phase listed Observational

Effects of Neurofeedback on Neural Function, Neuromodulation, and Chemotherapy-Induced Neuropathic Pain

NCT01278225
View directory record Official record
Conditions
Pain, Peripheral Neuropathy
Interventions
EEG biofeedback (BF) Group, Wait-List Control (WLC) Group, Follow UP Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 2, 2026, 3:45 PM EDT
Terminated Not applicable Interventional

3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

NCT00464724
View directory record Official record
Conditions
Prostate Cancer
Interventions
3T Magnetic Resonance Spectroscopic Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 2, 2026, 3:45 PM EDT
Recruiting Phase 2 Interventional

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

NCT07492680
View directory record Official record
Conditions
Solid Tumors
Interventions
BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Not applicable Interventional

Adaptive Intervention for Adolescents Following Inpatient Psychiatric Care

NCT05282225
View directory record Official record
Conditions
Suicide, Suicide, Attempted, Suicidal Ideation, Self Harm
Interventions
MI- Safety Plan, Texts messages, Monitoring, Portal follow-up, Booster call
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
13 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy Participants

NCT05826574
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Brensocatib, Rifampin, Esomeprazole
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

NCT00266097
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride, Oxaliplatin, radiation therapy
Drug · Radiation
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 2, 2026, 3:45 PM EDT
Recruiting Not applicable Interventional

Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain Injury

NCT05236010
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
rTMS, HD-tDCS, Attention Process Training
Device · Other
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 59 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Minneapolis, Minnesota • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors

NCT03926013
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-63898081
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
San Francisco, California • Bethesda, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 2, 2026, 3:45 PM EDT
Terminated Not applicable Interventional

3-month Aerobic and Resistance Exercise Intervention for Individuals Diagnosed With Melanoma

NCT03825913
View directory record Official record
Conditions
Melanoma
Interventions
Exercise Intervention, Wellness Intervention
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat Tablets in Healthy Adults

NCT05284760
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
Fruquintinib, Itraconazole, Rifampin
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Not applicable Interventional

Exercise for Anxiety

NCT04638946
View directory record Official record
Conditions
Anxiety
Interventions
Titration to high intensity exercise (T-HIE), Low intensity exercise prescription
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow

NCT05087108
View directory record Official record
Conditions
Venous Thromboses, Venous Stasis
Interventions
OsciPulse system, Reference Therapy 1, Refence Therapy 2
Device
Lead sponsor
OsciFlex LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 2, 2026, 3:45 PM EDT
Terminated Not applicable Interventional

The Nightmare Augmented Protocol for Treatment of Nightmares in Veterans With PTSD

NCT05120674
View directory record Official record
Conditions
PTSD
Interventions
NAP, CPT, ERRT, Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
VA Eastern Kansas
Federal
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Leavenworth, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

NCT04473690
View directory record Official record
Conditions
Covid19
Interventions
Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 2, 2026, 3:45 PM EDT
Not listed Phase 1Phase 2 Interventional

Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2

NCT04846010
View directory record Official record
Conditions
Sequelae of; Infection, Post Infection Glomerulonephritis, Post-Infectious Peripheral Neuralgia, Post-Infectious Disorder (Disorder), Post-Infectious Arthritis, Post-Infectious Polyneuritis, Post-Infectious Parkinsonism, Post-Infectious Hypothyroidism, Post Infectious Osteoarthritis, Anxiety Disorders, Depression, Depression, Anxiety, Depression, Bipolar, Insomnia, GERD, Gastro Esophageal Reflux, Hepatitis, Glomerulonephritis
Interventions
PurWet, FurFat, PurApo, PurPhl, PurClo, PurInf, Smoliv
Combination Product
Lead sponsor
All Natural Medicine Clinic, LLC
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Glycemic Response to High Amylose Rice

NCT01685879
View directory record Official record
Conditions
Diabetes Treatment (Pilot Study)
Interventions
Rice, Glucose Beverage
Other
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 40 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 31, 2014 · Synced Sep 2, 2026, 3:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Happy Mommy! Happy Baby! Study

NCT01700374
View directory record Official record
Conditions
Pregnancy, Stress, Psychological, Stress, Physiological, Maternal-fetal Relations
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
4
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 2, 2026, 3:45 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
XmAb942, Placebo
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
29
States / cities
Scottsdale, Arizona • Bradenton, Florida • Brandon, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

NCT01591850
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO5093151, atazanavir, ketoconazole, rifampicin, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Merritt Island, Florida
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 2, 2026, 3:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 2, 2026, 3:45 PM EDT